Arformoterol
Chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Inhalational; 15mcg administered twice a day (Morning and evening) by nebulizaion.
Hypersensitivity
Thyrotoxicosis; severe CV disorders e.g. ischaemic heart disease, tachyarrhythmias or severe heart burn; prolonged QT-interval. DM; pregnancy,lactation; children
Tremor, headache, tiredness, restlessness, dizziness, dry mouth, palpitation, Tachycardia, muscle cramps, nausea.
concomitant treatment with xanthine derivatives, steroids or diuretics may potentiate a possible hypokalaemic effect of b-agonists. Increased susceptibility to cardiac arrhythmias in patients treated with digitalis. concomitant use with quinidine, disopyramide, procainamide, phenothiazines, antihistamines, MAOI or TCAs can prolong the QT-interval and increase the risk of ventricular arrhythmias. L-dopa, L-thyroxine, Oxytocin and alcohol can impair cardiac tolerance towards b2-sympathomimetics. b